These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 16896660

  • 1. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Langen HJ, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [Abstract] [Full Text] [Related]

  • 3. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Scheiderbauer J, Machulla HJ, Dittmann H, Vonthein R, Bares R.
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):263-9. PubMed ID: 16270214
    [Abstract] [Full Text] [Related]

  • 4. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Dittmann H, Langen HJ, Bares R.
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [Abstract] [Full Text] [Related]

  • 5. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
    Tönnies S, Bauer TT, Misch D, Boch C, Blum T, Bittner RC, Förster GJ, Kollmeier J.
    Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
    [Abstract] [Full Text] [Related]

  • 6. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 7. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
    Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, Bares R.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
    [Abstract] [Full Text] [Related]

  • 8. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP, Correa AM, Hofstetter W, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.
    Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
    [Abstract] [Full Text] [Related]

  • 9. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B.
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
    Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, van Mourik JC, Postmus PE, Boers M, Grijseels EW, Teule GJ, Uyl-de Groot CA, PLUS study group.
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ.
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [Abstract] [Full Text] [Related]

  • 12. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [Abstract] [Full Text] [Related]

  • 13. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW, Yu JM, Xing LG.
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
    Tauhardt E, Reissig A, Winkens T, Freesmeyer M.
    Nuklearmedizin; 2014 Jan; 53(5):197-204. PubMed ID: 24986272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.